News | Published:

CD47 checkpoint data supercharge Stanford spinout IPO

Nature Biotechnology volume 36, pages 671672 (2018) | Download Citation

  • An Addendum to this article was published on 11 October 2018

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 26 September 2018

    This News Analysis described ongoing trials for drugs targeting CD47. However, the article omitted mention of a clinical trial with an anti-CD47 antibody from Tioma Therapeutics, which was terminated on the death of the first patient dosed. This fatality, potentially ascribed to red cell agglutination, may have some bearing on other trials with anti-CD47 antibodies.

Author information


  1. Somerville, Massachusetts

    • Elie Dolgin


  1. Search for Elie Dolgin in:

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing